First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup, announced the first patient enrolled in a Phase I dose-escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC).
